Juvenescence
Douglas · Founded 2016
About Juvenescence
Juvenescence Limited is a British Virgin Islands-based holding company that invests in human aging and longevity. Juvenescence has raised $111M to build an ecosystem and pipeline of assets targeting aging, age-related disease, and regeneration. Juvenescence believes that recent scientific and medical advances will enable the development of therapeutics that meaningfully extend human healthspan and eventually lifespan. A meaningful increase in lifespan in the already aging world will have profound implications on all sectors of society, and in particular healthcare, education, insurance, and leisure. The company creates and partners with new companies with longevity-related therapeutics, by in-licensing compounds from academia and industry, or forming joint ventures with the foremost longevity scientists and leading research institutions. Their work is based on a novel scientific understanding of the underlying biological causes of aging, to create evidence-based therapeutics that can treat diseases of aging. Juvenescence's goal is to extend both lifespan and healthspan, by developing therapeutics that slow aging and promote juvenescence.
Company Facts
- Founded: 2016
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $295.2M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2025)
- Website: juvlabs.com
- Phone: 441624639396
Industries & Categories
Biopharma, Biotechnology, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/juvenescence-40606 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.